{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T22:21:42Z","timestamp":1776205302035,"version":"3.50.1"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>This account describes how orally administered Arsenic-trioxide (ATO) therapy influences the epidemiology of acute promyelocytic leukaemia (APL), and how the experience that ensued may expand the indications for oral ATO as a treatment for diseases\/disorders other than APL. Over the last two decades, experience with APL patients in Hong Kong treated with an oral regimen comprising ATO, all-trans retinoic acid (ATRA), and ascorbic acid (also known as \u201cAAA\u201d) has confirmed a dramatic improvement in overall survival. Over that period, there has been an estimated 60-fold increase in the prevalence of APL (proportion of surviving APL patients in the population on December 31 including those deemed to be \u2018cured\u2019). In contrast to regimens entailing intravenous (IV) ATO, the consequential therapeutic benefits of using oral ATO have been achieved with much less patient inconvenience and quality of life disruption, reduced burdens on health care facilities (hospitalisations and staff involvement), and much enhanced affordability (retail drug &amp;amp; other cost reductions). Numerous experimental and a few clinical studies suggest that ATO may also have a therapeutic role in many other diseases\/disorders. Several such diseases (e.g. autoimmune disorders &amp;amp; idiopathic pulmonary fibrosis) are far more prevalent than APL, which means that very large numbers of patients may potentially benefit from ATO treatment, even if its efficacy is limited to selected populations with these diseases. The known safety of oral ATO and its advantages over repeated long-term IV delivery suggests that this route be used in future clinical studies of its possible role in treating such patients. If the clinical utility of oral ATO treatment is validated for patients enduring any such non-APL diseases, very large numbers of patients may stand to benefit.<\/jats:p>","DOI":"10.3389\/fonc.2022.1026478","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T05:17:32Z","timestamp":1668748652000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyond"],"prefix":"10.3389","volume":"12","author":[{"given":"Cyrus R.","family":"Kumana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yok-Lam","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harinder","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1111\/j.0954-6820.1957.tb00124.x","article-title":"Acute promyelocytic leukemia","volume":"159","author":"Hillestad","year":"1957","journal-title":"Acta Med Scand"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.391","article-title":"Curative strategies in acute promyelocytic leukemia","volume":"2008","author":"Tallman","year":"2008","journal-title":"ASH Education Program Book"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24950","article-title":"Acute promyelocytic leukemia and chronic lymphocytic leukemia diagnosed concurrently","volume":"93","author":"Coombs","year":"2018","journal-title":"Am J Hematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40487-018-0091-5","article-title":"Acute promyelocytic leukemia: A history over 60 years-from the most malignant to the most curable form of acute leukemia","volume":"7","author":"Thomas","year":"2019","journal-title":"Oncol Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1521-6926(03)00065-3","article-title":"The epidemiology of acute promyelocytic leukaemia","volume":"16","author":"Douer","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27623","article-title":"Acute promyelocytic leukemia: a population-based study on incidence and survival in the united states, 1975-2008","volume":"118","author":"Chen","year":"2012","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.21037\/sci.2019.10.03","article-title":"Incidence of acute promyelocytic leukemia across Europe: results of RARECAREnet-a population-based study","volume":"6","author":"Dinmohamed","year":"2019","journal-title":"Stem Cell Investig"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004789","article-title":"Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study","volume":"5","author":"Gill","year":"2021","journal-title":"Blood Adv"},{"key":"B9","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.21203\/rs.3.rs-1610362\/v1","article-title":"Epidemiology and outcomes of acute promyelocytic leukaemia in the era of all-trans retinoic acid: a retrospective analysis","volume":"23","author":"Gill","year":"2022","journal-title":"The Lancet Oncology"},{"key":"B10","article-title":"Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies","volume":"58","author":"Kumana","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01294","article-title":"Resurrection of oral arsenic trioxide for treating acute promyelocytic leukaemia: A historical account from bedside to bench to bedside","volume":"10","author":"Kumana","year":"2020","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0054","article-title":"Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety","volume":"108","author":"Siu","year":"2006","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32180","article-title":"Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study","volume":"125","author":"Gill","year":"2019","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.1183424","article-title":"Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML","volume":"328","author":"Zhang","year":"2010","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1717","article-title":"Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4\/ubiquitin-mediated pathway","volume":"10","author":"Lallemand-Breitenbach","year":"2008","journal-title":"Nat Cell Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1716","article-title":"RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation","volume":"10","author":"Tatham","year":"2008","journal-title":"Nat Cell Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15925","article-title":"High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro","volume":"8","author":"Noguera","year":"2017","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.7.1043","article-title":"Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia","volume":"189","author":"Lallemand-Breitenbach","year":"1999","journal-title":"J Exp Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.180290497","article-title":"Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins","volume":"97","author":"Rego","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131121","article-title":"Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia","volume":"210","author":"Dos Santos","year":"2013","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.1.268","article-title":"Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system","volume":"93","author":"Dai","year":"1999","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.3.805","article-title":"Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells","volume":"98","author":"Grad","year":"2001","journal-title":"Blood"},{"key":"B23","article-title":"Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed\/refractory multiple myeloma","volume":"8","author":"Bahlis","year":"2002","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/jbt.20223","article-title":"Differential effect of ascorbic acid and n-acetyl-L-cysteine on arsenic trioxide-mediated oxidative stress in human leukemia (HL-60) cells","volume":"22","author":"Yedjou","year":"2008","journal-title":"J Biochem Mol Toxicol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-354530","article-title":"Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study","volume":"118","author":"Au","year":"2011","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/S1470-2045(22)00410-7","article-title":"Epidemiology and outcomes of acute promyelocytic leukaemia in the era of all-trans retinoic acid (ATRA) chemotherapy and arsenic trioxide plus ATRA: a retrospective analysis","volume":"23","author":"Gill","year":"2022","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0738-y","article-title":"Arsenic trioxide for treating acute promyelocytic leukaemia: an evidence review group perspective of a NICE single technology appraisal","volume":"37","author":"Ramaekers","year":"2019","journal-title":"PharmacoEconomics"},{"key":"B28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1634\/theoncologist.6-suppl_2-17","article-title":"Arsenic trioxide: an emerging therapy for multiple myeloma","author":"Munshi","year":"2001","journal-title":"Oncologist"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-020610","article-title":"Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL\/lpr mice","volume":"108","author":"Bobe","year":"2006","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1866-2","article-title":"Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1","volume":"93","author":"Lo","year":"2014","journal-title":"Ann Hematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2014.2364","article-title":"Downregulation of thymidylate synthase with arsenic trioxide in lung adenocarcinoma","volume":"44","author":"Lam","year":"2014","journal-title":"Int J Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-611459","article-title":"Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells","volume":"125","author":"Martelli","year":"2015","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-612416","article-title":"Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells","volume":"125","author":"El Hajj","year":"2015","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-015-0143-3","article-title":"Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9","volume":"8","author":"Chau","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.311","article-title":"Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma","volume":"31","author":"Piao","year":"2017","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15011","article-title":"Old dog, new trick: Trivalent arsenic as an immunomodulatory drug","volume":"177","author":"Ye","year":"2020","journal-title":"Br J Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-019-1691-x","article-title":"Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization","volume":"63","author":"Liu","year":"2020","journal-title":"Sci China Life Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"115972","DOI":"10.1016\/j.taap.2022.115972","article-title":"Arsenic trioxide inhibits the functions of lung fibroblasts derived from patients with idiopathic pulmonary fibrosis","volume":"441","author":"Joannes","year":"2022","journal-title":"Toxicol Appl Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu142","article-title":"Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma","volume":"25","author":"Gill","year":"2014","journal-title":"Ann Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13075-021-02454-6","article-title":"Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic)","volume":"23","author":"Hamidou","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-020-01829-x","article-title":"Arsenic trioxide ameliorates experimental autoimmune encephalomyelitis in C57BL\/6 mice by inducing CD4+ T cell apoptosis","volume":"17","author":"An","year":"2020","journal-title":"J Neuroinflamm"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s11658-020-00236-7","article-title":"Arsenic trioxide as a novel anti-glioma drug: a review","volume":"25","author":"Fang","year":"2020","journal-title":"Cell Mole Biol Lett"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1191\/0961203306lu2305xx","article-title":"Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden","volume":"15","author":"Danchenko","year":"2006","journal-title":"Lupus"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex260","article-title":"The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies","volume":"56","author":"Rees","year":"2017","journal-title":"Rheumatol (Oxf)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000480","article-title":"Epidemiology of systemic lupus erythematosus: an update","volume":"30","author":"Stojan","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq127","article-title":"Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics","volume":"49","author":"Englund","year":"2010","journal-title":"Rheumatol (Oxf)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/art.27425","article-title":"Is the incidence of rheumatoid arthritis rising?: results from Olmsted county, Minnesota, 1955-2007","volume":"62","author":"Myasoedova","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200367","article-title":"The prevalence of rheumatoid arthritis: A systematic review of population-based studies","volume":"48","author":"Almutairi","year":"2021","journal-title":"J Rheumatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12931-021-01791-z","article-title":"Global incidence and prevalence of idiopathic pulmonary fibrosis","volume":"22","author":"Maher","year":"2021","journal-title":"Respir Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa177","article-title":"Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea","volume":"51","author":"Ogura","year":"2021","journal-title":"Jpn J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1026478\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T10:17:00Z","timestamp":1701425820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1026478\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":50,"alternative-id":["10.3389\/fonc.2022.1026478"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1026478","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"article-number":"1026478"}}